RP HPLC Method Development and Validation for Estimation of Orlistat in Pharmaceutical Dosage Forms
Pharmaceutical Science-Pharmaceutical analysis
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P257-266Keywords:
HPLC, Orlistat, Suitability, Precision and Stability.Abstract
Orlistat is an anti-obesity drug that inhibits the secretion of gastric and pancreatic lipases. Normally lipase breakdown triglyceride in the intestine as a result of metabolism. Despite the numerous advantages of this drug, researchers are facing problems with estimation by HPLC because limited methods are available; only United State Pharmacopoeia (USP) method is most reliable and effective. The present work aimed to develop an RP- HPLC method for determining orlistat in floating microcapsules. Considering the virtual reality in drug testing, quality control of dosage forms is the main criterion to be followed in the Pharmaceutical industry, which is to establish the procedures undertaken to ensure the identity and purity of a particular dosage form. Syncronis C18, 150mm x 4.6mm, 3μm column were used. Isocratic elution was performed with ACN:Water mixture. The flow rate was 2.0 mL min-1 and UV detection was at 205 nm. Caffeine was used as an internal standard. The developed method was validated according to the ICH guidelines and found to be linear within the range 150-600 ppm of Orlistat. In addition, this method was validated for its suitability, accuracy, precision, selectivity, robustness, and ruggedness per the ICH guidelines. The results HPLC analytical method validation was suitable for the quantitative and qualitative analysis of orlistat and it showed that this method could be successfully utilized for the identification and quantification of orlistat in any dosage form, with high resolution, accuracy, and precision.
References
Qi X. Review of the clinical effect of orlistat. IOP Conf S Mater Sci Eng. 2017;301:012063.
Pubchem. Orlistat [online]; 2022. Available from: ncbi.nlm.nih.gov [cited Jun 2 2022]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/orlistat.
Zaid AN, Zohud N, E’layan B, Aburadi T, Jaradat N, Ali I et al. Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules. Drug Des Dev Ther. 2017;11:3291-8. doi: 10.2147/DDDT.S138926, PMID 29200824.
Çelebier M, Reçber T, Koçak E, Altinöz S. RP-HPLC method development and validation for estimation of Rivaroxaban in pharmaceutical dosage forms. Braz J Pharm Sci. 2013;49(2):359-66. doi: 10.1590/S1984-82502013000200018.
ICH Official web site. ICH [internet]; 2022. Ich.org [cited Jun 11 2022]. Available from: https://www.ich.org/page/quality-guidelines.
Vidushi Y. A review on HPLC method development and validation, RJLBPCS. 2017;2(6):178.
Sahu PK. An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal. 2017;5(6):1-62.
Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness: ruggedness tests in method validation. J Pharm Biomed Anal. 2001;24(5-6):723-53. doi: 10.1016/s0731-7085(00)00529-x, PMID 11248467.
Callao MP. Multivariate experimental design in environmental analysis. TrAC Trends Anal Chem. 2014; 62:86-92. doi: 10.1016/j.trac.2014.07.009.
US FDA. Pharmaceutical cGMP for the 21st Century – A Risk-Based Approach: second Progress Report and Implementation Plan Introduction. Rockville, MD: Food and Drug Administration; 2003.
US FDA. Guidance for industry: PAT – A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Food and Drug Administration.
Rockville MD, 2004.
Dejaegher B, Vander Heyden YV. Ruggedness and robustness testing. J Chromatogr A. 2007;1158(1-2):138-57. doi: 10.1016/j.chroma.2007.02.086, PMID 17379230.
Dejaegher B, Vander Heyden Y. The use of experimental design in separation science. Acta Chromatogr. 2009;21(2):161-201. doi: 10.1556/AChrom.21.2009.2.1.
Del Castillo E. Process optimization a statistical approach. New York: Springer; 2007.
Karageorgou E, Samanidou V. Youden test application in robustness assays during method validation. J Chromatogr A. 2014;1353:131-9. doi: 10.1016/j.chroma.2014.01.050, PMID 24508395.
Garg NK, Sharma G, Singh B, Nirbhavane P, Katare OP. Quality by design (QbD)-based development and optimization of a simple, robust RP HPLC method for the estimation of methotrexate. J Liq Chromatogr Relat Technol. 2015;38(17):1629-37. doi: 10.1080/10826076.2015.1087409.
ICH. Q2 (R1) validation of analytical procedures: text and methodology. International Conference on Harmonization. Geneva: International Federation of Pharmaceutical Manufacturers Associations; 2005.
ICH. Q2A. Text on validation of analytical procedures, international Conference on Harmonization. Geneva; 1994.
Available from: standardbase.com. Orlistat drug profile | Dan.com [internet]; 2022. Dan.com [cited Jun 04 2022]. Available from: http://www.standardbase.com.
ICH. Q2A. Text on validation of analytical procedures, international Conference on Harmonization. Geneva; 1995.
FDA guidance for industry 2000. Analytical Procedures and Method Validation, Chemistry, Manufacturing, and Controls Documentation. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 August;29;Suppl 1:S49-52. PMID 18852857.
Rajan HV. Development and validation of HPLC method – a review. Int J Curr Res Pharm. 2015;1(2):55-68.
High-performance liquid chromatography – hplc [internet]; 2022. Chemguide. Available from: co.uk [cited Jun 1 2022]. Available from: https://chemguide.co.uk/analysis/chromatography/hplc.html.
Available from: McpolinOona.an. Introduction to HPLC for Pharmaceutical Analysis. Mourne Training Service. p. 11-2.
Scribd. PDF | Acid dissociation constant | Solubility [internet]; 2022. Physico-Chemical Properties of Drugs [cited Jun 3 2022]. Available from: https://www.scribd.com/presentation/331031311/Physico-chemical-Properties-of-Drugs.
Malviya R, Bansal V, Palo P, Sharma PK. High performance liqui chromatography: A short review. J Glob Pharm Technol. 2010;2(5):22-3.
Pratap B. Importance of RP-HPLC In Analytical method development: a review. Int J Novel Trends Pharm Sci. 2013;3(1):15-23.
Int J Novel Trends Pharm Sci. 2013;3(1):15-23.
Lindholm J. Development and Validation of HPLC method for Analytical and Preparative Purpose. Acta Universities Upsaliensis Uppsala. 2004; 13-4.
Snyder LR, Kirkland JJ, Glach JL. Practical HPLC method development. 2nd ed. New York: John Wiley & Sons; 1997. p. 233-91.
Sethi PD [introduction]. High performance liquid chromatography. 1st ed. New Delhi: CBS Publishers; 2001. p. 1-28.
Belal F, Sharaf El-Din AH, El-Awady M. Stability-indicating HPLC method for the determination of atenolol in pharmaceutical preparations. J Chromatogr Sep Tech. 2013;4(1):1-7.
Kachhadia PK, Doshi AS, Hitendra S. Joshi Development and validation of a stability indicating high performance liquid chromatographic (HPLC) method for atenolol and hydrochlorothiazide in bulk drug and tablet formulation. Int J Chem Tech Res. 2013;1(3):654-62.
Mustafa celebier, Tuba recber. RP-HPLC method development and validation for estimation of Rivaroxaban in pharmaceutical dosage forms. Braz J Pharm Sci. 2013;49(2).
Dr. Suyog J, Dr. Milind P. Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients. Int J Pharm Biol Sci. 2011;2(1):179-87.
Devanaboyina N, Satyanarayana T, Ganga Rao B. Simultaneous determination of olmesartan and hydrochlorothiazide in combined pharmaceutical dosage form by Rp-Hplc method. Int J Pharm Biol Sci. 2012;3(2):107-15.
Published
How to Cite
Issue
Section
Copyright (c) 2022 V. Vivekanandan, D. Kumudha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
